US20090093482A1 - Therapeutic compositions and methods - Google Patents
Therapeutic compositions and methods Download PDFInfo
- Publication number
- US20090093482A1 US20090093482A1 US12/147,220 US14722008A US2009093482A1 US 20090093482 A1 US20090093482 A1 US 20090093482A1 US 14722008 A US14722008 A US 14722008A US 2009093482 A1 US2009093482 A1 US 2009093482A1
- Authority
- US
- United States
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- hydroxy
- oxo
- methylbutan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1 Chemical compound CC(C)C1=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC2=CC=CC=C2)NC(=O)OCC2=CN=CS2)CC2=CC=CC=C2)=CS1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 description 5
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/147,220 US20090093482A1 (en) | 2007-06-29 | 2008-06-26 | Therapeutic compositions and methods |
US14/281,790 US20140343062A1 (en) | 2007-06-29 | 2014-05-19 | Method of treating a viral infection using elvitegravir combinations |
US15/298,070 US20170136000A1 (en) | 2007-06-29 | 2016-10-19 | Method of treating a viral infection using elvitegravir combinations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94732507P | 2007-06-29 | 2007-06-29 | |
US12/147,220 US20090093482A1 (en) | 2007-06-29 | 2008-06-26 | Therapeutic compositions and methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/281,790 Continuation US20140343062A1 (en) | 2007-06-29 | 2014-05-19 | Method of treating a viral infection using elvitegravir combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090093482A1 true US20090093482A1 (en) | 2009-04-09 |
Family
ID=39817166
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/666,995 Abandoned US20110009411A1 (en) | 2007-06-29 | 2008-06-26 | Therapeutic compositions and the use thereof |
US12/147,220 Abandoned US20090093482A1 (en) | 2007-06-29 | 2008-06-26 | Therapeutic compositions and methods |
US14/281,790 Abandoned US20140343062A1 (en) | 2007-06-29 | 2014-05-19 | Method of treating a viral infection using elvitegravir combinations |
US15/298,070 Abandoned US20170136000A1 (en) | 2007-06-29 | 2016-10-19 | Method of treating a viral infection using elvitegravir combinations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/666,995 Abandoned US20110009411A1 (en) | 2007-06-29 | 2008-06-26 | Therapeutic compositions and the use thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/281,790 Abandoned US20140343062A1 (en) | 2007-06-29 | 2014-05-19 | Method of treating a viral infection using elvitegravir combinations |
US15/298,070 Abandoned US20170136000A1 (en) | 2007-06-29 | 2016-10-19 | Method of treating a viral infection using elvitegravir combinations |
Country Status (21)
Country | Link |
---|---|
US (4) | US20110009411A1 (es) |
EP (1) | EP2167089A1 (es) |
JP (3) | JP5547067B2 (es) |
KR (1) | KR20100028656A (es) |
CN (2) | CN101743004A (es) |
AP (1) | AP2490A (es) |
AR (1) | AR067184A1 (es) |
AU (1) | AU2008270634B2 (es) |
BR (1) | BRPI0813955A2 (es) |
CA (1) | CA2691736A1 (es) |
CO (1) | CO6251236A2 (es) |
EA (1) | EA200971096A1 (es) |
EC (1) | ECSP109889A (es) |
IL (1) | IL202745A0 (es) |
MX (1) | MX2009013828A (es) |
NZ (1) | NZ582089A (es) |
SG (1) | SG182228A1 (es) |
TW (1) | TW200916103A (es) |
UA (1) | UA103881C2 (es) |
WO (1) | WO2009006203A1 (es) |
ZA (1) | ZA201000468B (es) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070219243A1 (en) * | 2005-12-30 | 2007-09-20 | Kearney Brian P | Method for improving the pharmacokinetics of HIV integrase inhibitors |
US20090093467A1 (en) * | 2007-06-29 | 2009-04-09 | Gilead Sciences, Inc. | Therapeutic compositions and methods |
US20090099366A1 (en) * | 2007-09-11 | 2009-04-16 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US20100189687A1 (en) * | 2007-02-23 | 2010-07-29 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US7825252B2 (en) | 2006-09-12 | 2010-11-02 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
WO2013082476A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
US8877931B2 (en) | 2012-08-03 | 2014-11-04 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US9139541B2 (en) | 2006-07-07 | 2015-09-22 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201591353A1 (ru) | 2008-05-02 | 2016-01-29 | Джилид Сайэнс, Инк. | Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента |
WO2011127244A2 (en) * | 2010-04-09 | 2011-10-13 | Bristol-Myers Squibb Company | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT |
US20130274254A1 (en) * | 2010-12-21 | 2013-10-17 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 (cyp3a4) |
WO2013130766A1 (en) * | 2012-03-01 | 2013-09-06 | Gilead Sciences, Inc. | Spray dried formulations |
CA3012242C (en) | 2012-12-21 | 2021-11-02 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
NO2865735T3 (es) | 2013-07-12 | 2018-07-21 | ||
JP6411491B2 (ja) | 2013-07-12 | 2018-10-24 | ギリアード サイエンシス インコーポレーテッド | 多環式カルバモイルピリドン化合物およびhiv感染症を処置するためのその使用 |
NO2717902T3 (es) | 2014-06-20 | 2018-06-23 | ||
TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
AU2016244035B2 (en) | 2015-04-02 | 2018-11-01 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
EP3706762A4 (en) | 2017-12-07 | 2021-09-01 | Emory University | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTIVIRAL USES IN RELATION TO IT |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196438A (en) * | 1989-12-11 | 1993-03-23 | Hoffmann-La Roche Inc. | Amino acid derivatives |
US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5541206A (en) * | 1989-05-23 | 1996-07-30 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
US20050239819A1 (en) * | 2002-11-20 | 2005-10-27 | Motohide Satoh | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors |
US20050288326A1 (en) * | 2004-05-21 | 2005-12-29 | Yuji Matsuzaki | Combination therapy |
US20070219243A1 (en) * | 2005-12-30 | 2007-09-20 | Kearney Brian P | Method for improving the pharmacokinetics of HIV integrase inhibitors |
US20080125594A1 (en) * | 2006-09-12 | 2008-05-29 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US20090093467A1 (en) * | 2007-06-29 | 2009-04-09 | Gilead Sciences, Inc. | Therapeutic compositions and methods |
US20090099366A1 (en) * | 2007-09-11 | 2009-04-16 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
US20090291952A1 (en) * | 2006-07-07 | 2009-11-26 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US20090324729A1 (en) * | 2008-05-02 | 2009-12-31 | Gilead Sciences, Inc. | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
US20110000941A1 (en) * | 2009-07-06 | 2011-01-06 | Volk J Patrick | Apparatus and System for Carrying a Digital Media Player |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060111933A1 (en) * | 2003-10-09 | 2006-05-25 | Steven Wheeler | Adaptive medical decision support system |
MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
US20060058286A1 (en) * | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
WO2007092802A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
-
2008
- 2008-06-26 KR KR1020107001984A patent/KR20100028656A/ko not_active Application Discontinuation
- 2008-06-26 UA UAA200913904A patent/UA103881C2/ru unknown
- 2008-06-26 MX MX2009013828A patent/MX2009013828A/es not_active Application Discontinuation
- 2008-06-26 AU AU2008270634A patent/AU2008270634B2/en not_active Ceased
- 2008-06-26 AP AP2009005083A patent/AP2490A/xx active
- 2008-06-26 NZ NZ582089A patent/NZ582089A/xx not_active IP Right Cessation
- 2008-06-26 BR BRPI0813955A patent/BRPI0813955A2/pt not_active IP Right Cessation
- 2008-06-26 JP JP2010515115A patent/JP5547067B2/ja not_active Expired - Fee Related
- 2008-06-26 EP EP20080781024 patent/EP2167089A1/en not_active Withdrawn
- 2008-06-26 CN CN200880022821A patent/CN101743004A/zh active Pending
- 2008-06-26 US US12/666,995 patent/US20110009411A1/en not_active Abandoned
- 2008-06-26 US US12/147,220 patent/US20090093482A1/en not_active Abandoned
- 2008-06-26 CN CN2013101948825A patent/CN103356622A/zh active Pending
- 2008-06-26 SG SG2012046926A patent/SG182228A1/en unknown
- 2008-06-26 AR ARP080102760A patent/AR067184A1/es not_active Application Discontinuation
- 2008-06-26 CA CA002691736A patent/CA2691736A1/en not_active Abandoned
- 2008-06-26 EA EA200971096A patent/EA200971096A1/ru unknown
- 2008-06-26 TW TW097123981A patent/TW200916103A/zh unknown
- 2008-06-26 WO PCT/US2008/068351 patent/WO2009006203A1/en active Application Filing
-
2009
- 2009-12-15 IL IL202745A patent/IL202745A0/en unknown
- 2009-12-21 CO CO09146050A patent/CO6251236A2/es not_active Application Discontinuation
-
2010
- 2010-01-21 ZA ZA2010/00468A patent/ZA201000468B/en unknown
- 2010-01-21 EC EC2010009889A patent/ECSP109889A/es unknown
-
2013
- 2013-07-08 JP JP2013142320A patent/JP5769762B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-19 US US14/281,790 patent/US20140343062A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015094705A patent/JP2015143277A/ja not_active Withdrawn
-
2016
- 2016-10-19 US US15/298,070 patent/US20170136000A1/en not_active Abandoned
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5541206A (en) * | 1989-05-23 | 1996-07-30 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5196438A (en) * | 1989-12-11 | 1993-03-23 | Hoffmann-La Roche Inc. | Amino acid derivatives |
US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
US20050239819A1 (en) * | 2002-11-20 | 2005-10-27 | Motohide Satoh | 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors |
US20050288326A1 (en) * | 2004-05-21 | 2005-12-29 | Yuji Matsuzaki | Combination therapy |
US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
US20070219243A1 (en) * | 2005-12-30 | 2007-09-20 | Kearney Brian P | Method for improving the pharmacokinetics of HIV integrase inhibitors |
US20090291952A1 (en) * | 2006-07-07 | 2009-11-26 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US20080125594A1 (en) * | 2006-09-12 | 2008-05-29 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US20110160458A1 (en) * | 2006-09-12 | 2011-06-30 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US20090093467A1 (en) * | 2007-06-29 | 2009-04-09 | Gilead Sciences, Inc. | Therapeutic compositions and methods |
US20100331331A1 (en) * | 2007-06-29 | 2010-12-30 | Therapeutic Compositons And Use Thereof | Therapeutic compositions and the use thereof |
US20090099366A1 (en) * | 2007-09-11 | 2009-04-16 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US20100292480A1 (en) * | 2007-09-11 | 2010-11-18 | Gilead Sciences, Inc | Process and intermediates for preparing integrase inhibitors |
US20090324729A1 (en) * | 2008-05-02 | 2009-12-31 | Gilead Sciences, Inc. | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
US20110000941A1 (en) * | 2009-07-06 | 2011-01-06 | Volk J Patrick | Apparatus and System for Carrying a Digital Media Player |
Non-Patent Citations (2)
Title |
---|
Edwin DeJesus et al, JAIDS, 2006, 43(1), 1-5. * |
Katz et al, Drug and Alcohol Dependence, 2007, 91, 269-278. * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070219243A1 (en) * | 2005-12-30 | 2007-09-20 | Kearney Brian P | Method for improving the pharmacokinetics of HIV integrase inhibitors |
US9139541B2 (en) | 2006-07-07 | 2015-09-22 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US7825252B2 (en) | 2006-09-12 | 2010-11-02 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US8796459B2 (en) | 2006-09-12 | 2014-08-05 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US8324244B2 (en) | 2006-09-12 | 2012-12-04 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US9891239B2 (en) * | 2007-02-23 | 2018-02-13 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US20100189687A1 (en) * | 2007-02-23 | 2010-07-29 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US20090093467A1 (en) * | 2007-06-29 | 2009-04-09 | Gilead Sciences, Inc. | Therapeutic compositions and methods |
US8440831B2 (en) | 2007-09-11 | 2013-05-14 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US8759525B2 (en) | 2007-09-11 | 2014-06-24 | Gilhead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US8153801B2 (en) | 2007-09-11 | 2012-04-10 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
US20100292480A1 (en) * | 2007-09-11 | 2010-11-18 | Gilead Sciences, Inc | Process and intermediates for preparing integrase inhibitors |
US20090099366A1 (en) * | 2007-09-11 | 2009-04-16 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
WO2013082476A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
EP3750544A2 (en) | 2011-11-30 | 2020-12-16 | Emory University | Jak inhibitors for use in the prevention or treatment of viral infection |
US8877931B2 (en) | 2012-08-03 | 2014-11-04 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
ZA201000468B (en) | 2011-06-29 |
US20140343062A1 (en) | 2014-11-20 |
NZ582089A (en) | 2013-01-25 |
AU2008270634A1 (en) | 2009-01-08 |
CA2691736A1 (en) | 2009-01-08 |
AP2009005083A0 (en) | 2009-12-31 |
US20110009411A1 (en) | 2011-01-13 |
US20170136000A1 (en) | 2017-05-18 |
IL202745A0 (en) | 2010-06-30 |
AP2490A (en) | 2012-10-04 |
EP2167089A1 (en) | 2010-03-31 |
ECSP109889A (es) | 2010-03-31 |
JP2015143277A (ja) | 2015-08-06 |
UA103881C2 (ru) | 2013-12-10 |
WO2009006203A1 (en) | 2009-01-08 |
EA200971096A1 (ru) | 2010-08-30 |
AR067184A1 (es) | 2009-09-30 |
CO6251236A2 (es) | 2011-02-21 |
TW200916103A (en) | 2009-04-16 |
BRPI0813955A2 (pt) | 2017-05-09 |
AU2008270634B2 (en) | 2014-01-16 |
JP2013199494A (ja) | 2013-10-03 |
SG182228A1 (en) | 2012-07-30 |
JP2010532373A (ja) | 2010-10-07 |
CN103356622A (zh) | 2013-10-23 |
CN101743004A (zh) | 2010-06-16 |
JP5547067B2 (ja) | 2014-07-09 |
KR20100028656A (ko) | 2010-03-12 |
MX2009013828A (es) | 2010-03-10 |
JP5769762B2 (ja) | 2015-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090093482A1 (en) | Therapeutic compositions and methods | |
AU2008270630B2 (en) | Therapeutic compositions and the use thereof | |
CA2635468C (en) | Methods for improving the pharmacokinetics of hiv integrase inhibitors | |
US20090233964A1 (en) | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GILEAD SCIENCES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KEARNEY, BRIAN P.;MATHIAS, ANITA A.;REEL/FRAME:021991/0041;SIGNING DATES FROM 20081203 TO 20081215 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |